Baroness Finlay of Llandaff Alert Sample


Alert Sample

View the Parallel Parliament page for Baroness Finlay of Llandaff

Information between 17th April 2024 - 7th May 2024

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Division Votes
23 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 25 Crossbench Aye votes vs 5 Crossbench No votes
Tally: Ayes - 203 Noes - 192
23 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 25 Crossbench Aye votes vs 6 Crossbench No votes
Tally: Ayes - 200 Noes - 192
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 38 Crossbench Aye votes vs 11 Crossbench No votes
Tally: Ayes - 240 Noes - 211
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 46 Crossbench Aye votes vs 1 Crossbench No votes
Tally: Ayes - 245 Noes - 208
17 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 42 Crossbench Aye votes vs 1 Crossbench No votes
Tally: Ayes - 247 Noes - 195
30 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and against the House
One of 9 Crossbench Aye votes vs 4 Crossbench No votes
Tally: Ayes - 67 Noes - 175
30 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and against the House
One of 21 Crossbench Aye votes vs 11 Crossbench No votes
Tally: Ayes - 209 Noes - 209
30 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and against the House
One of 32 Crossbench Aye votes vs 16 Crossbench No votes
Tally: Ayes - 222 Noes - 222
30 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 34 Crossbench Aye votes vs 12 Crossbench No votes
Tally: Ayes - 214 Noes - 208
30 Apr 2024 - Victims and Prisoners Bill - View Vote Context
Baroness Finlay of Llandaff voted Aye and in line with the House
One of 38 Crossbench Aye votes vs 10 Crossbench No votes
Tally: Ayes - 238 Noes - 217


Speeches
Baroness Finlay of Llandaff speeches from: Victims and Prisoners Bill
Baroness Finlay of Llandaff contributed 4 speeches (1,214 words)
Report stage
Tuesday 30th April 2024 - Lords Chamber
Leader of the House
Baroness Finlay of Llandaff speeches from: Covid-19 Vaccination: Coronary Disease
Baroness Finlay of Llandaff contributed 1 speech (121 words)
Tuesday 23rd April 2024 - Lords Chamber
Department of Health and Social Care
Baroness Finlay of Llandaff speeches from: NHS: Long-term Sustainability
Baroness Finlay of Llandaff contributed 1 speech (707 words)
Thursday 18th April 2024 - Lords Chamber
Department of Health and Social Care
Baroness Finlay of Llandaff speeches from: Cass Review
Baroness Finlay of Llandaff contributed 1 speech (253 words)
Wednesday 17th April 2024 - Lords Chamber
Department of Health and Social Care


Written Answers
Drugs: Prices
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Monday 22nd April 2024

Question to the Department of Health and Social Care:

To ask His Majesty's Government what progress they have made with the proposed amendments to the Part IX of the Drug Tariff, including any impact assessments on the future provision of medical technologies in the UK; how these proposals meet the ambitions of the Life Sciences Vision; and what steps they are taking to ensure that there is sufficient patient choice following the outcome of the consultation.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.

The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.

These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.

The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.

Drugs: Prices
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Monday 22nd April 2024

Question to the Department of Health and Social Care:

To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.

The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.

These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.

The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.

Tofersen
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Monday 22nd April 2024

Question to the Department of Health and Social Care:

To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.

Tofersen: Licensing
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Monday 22nd April 2024

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.




Baroness Finlay of Llandaff mentioned

Bill Documents
May. 03 2024
21st Report of the Delegated Powers and Regulatory Reform Committee
Post Office (Horizon System) Offences Bill 2023-24
Select Committee report

Found: Lindsay Baroness Chakrabarti Lord McLoughlin (Chair) Lord Cunningham of Felling Lord Rooker Baroness

May. 01 2024
19th Report of the Delegated Powers and Regulatory reform Committee
Zoological Society of London (Leases) Bill 2023-24
Select Committee report

Found: Lindsay Baroness Chakrabarti Lord McLoughlin (Chair) Lord Cunningham of Felling Lord Rooker Baroness

Apr. 26 2024
HL Bill 57-III Third marshalled list for Report
Victims and Prisoners Bill 2022-23
Amendment Paper

Found: BARONESS FINLAY OF LLANDAFF LORD THOMAS OF CWMGIEDD 109B _ Clause 30, page 30, line 36, at end

Apr. 22 2024
HL Bill 57-II(Rev) Revised second marshalled list for Report
Victims and Prisoners Bill 2022-23
Amendment Paper

Found: BARONESS FINLAY OF LLANDAFF LORD THOMAS OF CWMGIEDD 109B _ Clause 30, page 30, line 36, at end

Apr. 19 2024
HL Bill 57-II Second marshalled list for Report
Victims and Prisoners Bill 2022-23
Amendment Paper

Found: BARONESS FINLAY OF LLANDAFF 109B★_ Clause 30, page 30, line 36, at end insert “save in respect

Apr. 18 2024
18th Report of the Delegated Powers and Regulatory Reform Committee
Investigatory Powers (Amendment) Act 2024
Select Committee report

Found: Lindsay Baroness Chakrabarti Lord McLoughlin (Chair) Lord Cunningham of Felling Lord Rooker Baroness




Baroness Finlay of Llandaff - Select Committee Information

Calendar
Wednesday 1st May 2024 10:30 a.m.
Delegated Powers and Regulatory Reform Committee - Private Meeting
View calendar
Thursday 2nd May 2024 10 a.m.
Delegated Powers and Regulatory Reform Committee - Private Meeting
View calendar